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An antigen detection system, termed immuno-polymerase chain reaction (immuno-PCR), was developed in which a specific DNA molecule is used as the marker. A streptavidinprotein A chimera that possesses tight and specific binding affinity both for biotin and immunoglobulin G was used to attach a biotinylated DNA specifically to antigen-monoclonal antibody complexes that had been immobilized on microtiter plate wells. Then, a segment of the attached DNA was amplified by PCR. Analysis of the PCR products by agarose gel electrophoresis after staining with ethidium bromide allowed as few as 580 antigen molecules (9.6 x 10-22 moles) to be readily and reproducibly detected. Direct comparison with enzyme-linked immunosorbent assay with the use of a chimera-alkaline phosphatase conjugate demonstrates that enhancement (approximately x 105) in detection sensitivity was obtained with the use of immuno-PCR. Given the enormous amplification capability and specificity of PCR, this immuno-PCR technology has a sensitivity greater than any existing antigen detection system and, in principle, could be applied to the detection of single antigen molecules.
Antibody-based detection systems for specific antigens are a versatile and powerful tool for various molecular and cellular analyses and clinical diagnostics. The power of such systems originates from the considerable specificity of antibodies for their particular epitopes. A number of recent antibody technologies, including genetic engineering of antibody molecules (1) and the production of catalytic antibodies (2) and bispecific antibodies (3), are allowing a rapid expansion in the applications of antibodies. We were interested in further enhancing the sensitivity of antigen detection systems. This should facilitate the specific detection of rare antigens, which are pre- sent only in very small numbers, and thus could expand the application of antibodies to a wider variety of biological and nonbiological systems. Polymerase chain reaction (PCR) technology (4) has become a powerful tool in molecular biology and genetic engineering (5). The efficacy of PCR is based on its ability to amplify a specific DNA segment flanked by a set of primers. The enormous amplification capability of PCR allows the production of large amounts of specific DNA products, which can be detected by various methods. The extremely high specificity of PCR for a target sequence defined by a set of primers should avoid the generation of false signals from other nucleic acid molecules present in samples. We reasoned that the capability of antigen detection systems could be considerably enhanced and potentially broadened by coupling to PCR. Following these ideas, we have developed an antigen detection system, termed immuno-PCR, in which a specific antibody-DNA conjugate is used to detect antigens.
In immuno-PCR, a linker molecule with bispecific binding affinity for DNA and antibodies is used to attach a DNA molecule (marker) specifically to an antigen-antibody complex, resulting in the formation of a specific antigen-antibody-DNA conjugate. The attached marker DNA can be amplified by PCR with the appropriate primers. The presence of specific PCR products demonstrates that marker DNA molecules are attached specifically to antigen-antibody complexes, which indicates the presence of antigen. A streptavidin-protein A chimera that we recently designed (6) was used as the linker. The chimera has two independent specific binding abilities; one is to biotin, derived from the streptavidin moiety, and the other is to the Fc portion of an immunoglobulin G (IgG) molecule, derived from the protein A moiety. This bifunctional specificity both for biotin and antibody allows the specific conjugation of any biotinylated DNA molecule to antigen-antibody complexes.
To test the feasibility of this concept, we immobilized various amounts of an antigen on the surface of microtiter plate wells and detected them by immuno-PCR. Bovine serum albumin (BSA) was used as the antigen because of the availability of pure protein and monoclonal antibodies against it. The detection procedure used (7) cates that the biotinylated pUC19 was specifically attached to the antigen-monoclonal antibody complexes by the chimera. In contrast, almost no 260-bp fragment was observed in lanes 10 through 12, which came from wells without immobilized antigen. Quantitation of the 260-bp PCR product (Fig. 1B) Fig. 1A) (12) . Direct comparison with ELISA with the use of a chimera-alkaline phosphatase conjugate (Fig. 2) This extremely high sensitivity of immuno-PCR was achieved just with the use of agarose gel electrophoresis to detect Fig. 1 9 (Fig.  1A) , which demonstrates that the PCR amplification was not saturated below 0.96 amol of BSA. For wells that contained more antigen (lanes 1 through 5) , the PCR amplification was saturated. In principle, quantitation of PCR products below saturation should provide an estimate of the number of antigens (epitopes) after appropriate calibration with known numbers of antigen molecules. When more dilute chimera-pUC19 conjugates were used, saturation of PCR amplification occurred with larger amounts of the immobilized antigen (Fig. 3) . Thus, one can control the sensitivity of the system by varying the concentration of the conjugate. Other key factors, such as the concentration of antibody, the number of PCR amplification cycles, and the detection method for PCR products, can also be used to control the overall sensitivity of the system. In principle, the extremely high sensitivity of immuno-PCR should enable this technology to be applied to the detection of single antigen molecules; no method is currently available for this. The sensitivity of current antigen detection systems can be enhanced by at least a few orders of magnitude simply by the introduction of PCR. in Escherichia coli by means of the expression vector pTSAPA-2 and purified to homogeneity (6). The purified chimera was stored frozen at -70?C in 150 mM NaCI, 20 mM tris-CI (pH 7.5), 0.02% NaN3, and 6% sucrose. No appreciable changes in the biotin-and the IgG-binding ability were observed upon frozen storage. 10. We prepared the chimera-pUC19 conjugate by mixing the purified chimera (9) and the biotinylated pUC19 (8) at a molar ratio of biotin to biotin binding site of 1. The resulting conjugates contain four biotinylated pUC19 per chimera, which possesses four biotin binding sites (6). 
